Article
Comportamiento biológico de Blastocystis hominis en pacientes tratados con Secnidazol (Unidazol®)
Registro en:
RSVM 2008; 28:66-71
1317-973X
Autor
Guzmán de Rondón, Carmen T.
Vethencourt, Maria Alejandra
Galindo Pérez, Monica
Chacón, Nathalie
Wagner A., Carolina M.
Nessi Paduani, Anaibeth
Institución
Resumen
Blastocystis hominis, classified as Stramenopile, is the most frequent intestinal parasite in humans. In feces and cultures, forms
with a central body (FCB), granulose forms (GraF), as well as globulous and ameboid forms in binary division or in cysts are seen. Its
elevated prevalence, association with symptoms in humans, and lack of effective treatment, justified the evaluation of secnidazol (Unidazol
® ZOUZ-PHARMA) in 14 individuals (7 males and 7 females) infected with B. hominis, with ages between 5-79 years, who were
clinically and parasitologically evaluated before and after treatment; with one dose of the drug: 2 g for adults and 30 mg/Kg body weight
for children. In feces serial examinations we evaluated morphology, number of parasites per microscopic field (400X), reproductive
forms, and growth in culture. The study showed that in 14.3% (2/14) of patients the parasite was eliminated, and there was a significant
decrease of the number per field (p< 0.05), of the FCB (p= 0.001) and of GraF (p< 0.05) frequency in the rest, as well as a decrease of
positive direct examinations (p< 0.001). These preliminary results show that the drug in a single dose occasionally eradicated B. hominis,
decreased the excretion of vegetative forms and induced the occurrence of cysts.These studies should be continued. Comportamiento Biológico de Blastocystis sp. CDCH-UCV PI-090058002005 y parcialmente
por LABORATORIO ZUOZ PHARMA.